BIBF1120
Sponsors
Boehringer Ingelheim, Ulrik Lassen, AHS Cancer Control Alberta, National Taiwan University Hospital, Samsung Medical Center
Conditions
Ovarian NeoplasmsPlatinum-sensitiveRecurrent GlioblastomaRecurrent or Metastatic Salivary Gland Cancer of the Head and NeckSmall Cell Lung CancerUrothelial Carcinoma
Phase 2
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
CompletedNCT00710762
Start: 2006-03-31End: 2014-03-31Updated: 2016-08-15
BIBF 1120 in Recurrent Glioblastoma Multiforme
CompletedNCT01251484
Start: 2011-01-31End: 2012-08-31Updated: 2012-10-04
A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
WithdrawnNCT02152059
Start: 2014-07-31End: 2016-07-31Updated: 2016-07-06
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
NCT02278978
Start: 2014-10-31End: 2016-03-31Target: 129Updated: 2015-05-12
Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
NCT02558387
Start: 2014-11-30End: 2017-01-31Updated: 2015-11-20